Andrographolide enhances 5-fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells

Cancer Letters

Volumn 276, Issue 2, 2009, Pages 180-188

  Yang, Lu ^a   Wu, Dingfang ^a   Luo, Kewang ^a   Wu, Shihua ^a   Wu, Ping ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

5 Fluorouracil; Andrographolide; Apoptosis; Caspase 8 dependent; Hepatocellular carcinoma

Indexed keywords

ANDROGRAPHOLIDE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FLUOROURACIL; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; CONFORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIVER CELL CARCINOMA; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CYTOCHROMES C; DITERPENES; DRUG SYNERGISM; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; TUMOR SUPPRESSOR PROTEIN P53;

ANDROGRAPHIS PANICULATA;

EID: 60849083797     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.015     Document Type: Article

References (47)

1. Ozols R.F., Herbst R.S., and Colson Y.L. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J. Clin. Oncol. 25 (2007) 146-162
2. Carr B.I. Hepatocellular carcinoma: current management and future trends. Gastroenterology 127 (2004) S218-S224
3. Song T.J., Ip E.W., and Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 127 (2004) S248-S260
4. Cammà C., Schepis F., and Orlando A. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 (2002) 47-54
5. Poolsup N., Suthisisang C., Prathanturarug S., Asawamekin A., and Chanchareon U. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. J. Clin. Pharm. Ther. 29 (2004) 37-45
6. Shen Y.C., Chen C.F., and Chiou W.F. Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Brit. J. Pharmacol. 135 (2002) 399-406
7. Iruretagoyena M.I., Tobar J.A., and González P.A. Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J. Pharmacol. Exp. Ther. 312 (2005) 366-372
8. Calabrese C., Berman S.H., Babish J.G., and Standish L.J. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother. Res. 14 (2000) 333-338
9. Trivedi N.P., Rawal U.M., and Patel B.P. Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury. Integr. Cancer Ther. 6 (2007) 271-280
10. Rajagopal S., Kumar R.A., Deevi D.S., Satyanarayana C., and Rajagopalan R. Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J. Exp. Ther. Oncol. 3 (2003) 147-158
11. Cheung H.Y., Cheung S.H., and Li J. Andrographolide isolated from Andrographis paniculata induces cell cycle arrest and mitochondrial-mediated apoptosis in human leukemic HL-60 cells. Planta. Med. 71 (2005) 1106-1111
12. Li J., Cheung H.Y., Zhang Z., Chan G.K., and Fong W.F. Andrographolide induces cell cycle arrest at G2/M phase and cell death in HepG2 cells via alteration of reactive oxygen species. Eur. J. Pharmacol. 568 (2007) 31-44
13. Zhou J., Zhang S., Ong C.N., and Shen H.M. Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. Biochem. Pharmacol. 72 (2006) 132-144
14. Fitzgerald J.B., Schoeberl B., Nielsen U.B., and Sorger P.K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2 (2006) 458-466
15. Yeh P., and Kishony R. Networks from drug-drug surfaces. Mol. Syst. Biol. 3 (2007) 85
16. Jackman A.L., Kaye S., and Workman P. The combination of cytotoxic and molecularly targeted therapies-can it be done?. Drug Discov. Today 1 (2004) 445-454
17. Sampath D., Rao V.A., and Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22 (2003) 9063-9074
18. Park S.H., Nam E., and Park J. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann. Oncol. 19 (2008) 729-733
19. Ychou M., Viret F.K., and Ramar A. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother. Pharmacol. 62 (2008) 195-201
20. Kelsey C.R., Chino J.P., and Willett C.G. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 69 (2007) 770-776
21. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
22. Blagosklonny M.V. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 23 (2004) 2967-2975
23. Reed J.C. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol. Med. 22 (2001) 314-319
24. Wang H.G., and Reed J.C. Mechanisms of Bcl-2 protein function. Histol. Histopathol. 13 (1998) 521-530
25. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., and Korsmeyer S.J. Proapoptotic Bax and Bak: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
26. Nechushtan A., Smith C.L., Lamensdorf I., Yoon S.H., and Youle R.J. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J. Cell Biol. 153 (2001) 1265-1276
27. Wolter K.G., Hsu Y.T., Smith C.L., Nechushtan A., Xi X.G., and Youle R.J. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 139 (1997) 1281-1292
28. Yamaguchi H., Paranawithana S.R., Lee M.W., Huang Z., Bhalla K.N., and Wang H.G. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res. 62 (2002) 466-471
29. Eskes R., Desagher S., Antonsson B., and Martinou J.C. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell Biol. 20 (2000) 929-935
30. Marani M., Tenev T., Hancock D., Downward J., and Lemoine N.R. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol. Cell Biol. 22 (2002) 3577-3589
31. Yamaguchi H., and Wang H.G. Bcl-XL protects BimEL-induced Bax conformational change and cytochrome c release independent of interacting with Bax or BimEL. J. Biol. Chem. 277 (2002) 41604-41612
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Method. 65 (1983) 55-63
33. He Z., Ma W.Y., Hashimoto T., Bode A.M., Yang C.S., and Dong Z. Induction of apoptosis by caffeine is mediated by the p53, Bax and caspase 3 pathways. Cancer Res. 63 (2003) 4396-4401
34. Li P., Nijhawan D., and Budihardjo I. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
35. Kerr J.F., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Brit. J. Cancer 26 (1972) 239-257
36. Rello S., Stockert J.C., Moreno V., Gamez A., Pacheco M., and Juarranz A. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis 10 (2005) 201-208
37. Green D.R. Apoptotic pathways: paper wraps stone blunts scissors. Cell 102 (2000) 1-4
38. Hu H., Jiang C., Schuster T., Li G.X., Daniel P.T., and Lü J. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol. Cancer Ther. 5 (2006) 1873-1882
39. Backus H.H., Dukers D.F., and van Groeningen C.J. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann. Oncol. 12 (2001) 209-216
40. Yamamoto T., Nagano H., and Sakon M. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin. Cancer Res. 10 (2004) 7884-7895
41. Kuwana T., Bouchier-Hayes L., and Chipuk J.E. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17 (2005) 525-535
42. Chipuk J.E., Kuwana T., and Bouchier-Hayes L. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
43. Hockenbery D.M., Giedt C.D., O'Neill J.W., Manion M.K., and Banker D.E. Mitochondria and apoptosis: new therapeutic targets. Adv. Cancer Res. 85 (2002) 203-242
44. Ehrhardt H., Häcker S., and Wittmann S. Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene 27 (2008) 783-793
45. Carmody R.J., and Cotter T.G. Signalling apoptosis: a radical approach. Redox. Rep. 6 (2001) 77-90
46. Sauer H., Wartenberg M., and Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol. Biochem. 11 (2001) 173-186
47. Johnson T.M., Yu Z.X., Ferrans V.J., Lowenstein R.A., and Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 93 (1996) 11848-11852